Well, as far as provenge is concerned, there were no reported side effects from mpap cross reacting in those other organs so Im not concerned. Stroke is a vascular and not a neuronal event so I wouldnt become alarmist or be so bold as to postulate that this is the mechanism of why there was a slight increase in stroke amongst the provenge patients. Of course there is no real moi data to say there is nointeraction but safety was voted 17-0 at the ac based on the data presented. All these therapies will require long term follow up if approved.
If you read the paper you will see the only evidence they present of PAP outside prostate is in RT-PCR of mouse tissues. There is no second experiment (e.g. by Westerns or Northerns), and no examination of distributions in humans. Also vital information is missing (namely primers used for RT-PCR expression analysis, supposedly in a missing supplementary file that is nowhere to be seen). Overall a rather sloppy hasty effort, not what you would expect from Cancer Research. What is the rush to publish this? Why did the editors not say, more evidence needed, "approvable?"
Cunha et al. used primers from the EC region in both the secreted and this newly identified TM form of PAP, so it's not that the Cunha primers would have missed the TM form. OTOH they also only did RT-PCR.
Also I did a quick search of human ests and there are no clones of the form predicted in this new paper. This is something the reviewers should have asked for. It could exist, just be in very low abundance. There are mouse ests of TM-PAP though, so it could very well be that this is the form that is widely distributed in the mouse.
News 
Market Data 
Discover 
AI
